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The lead time and overdetection associated with prostate-specific antigen (PSA) screening, and generational improvements in all-
cause mortality, make prostate cancer outcome studies from the pre-PSA era difficult to interpret in a contemporary setting. We
developed a competing-risks hazard model to estimate the natural history of screen-detected prostate cancer, and the impact of
radical treatment on overall survival. The model of hazard of mortality was fitted to clinical outcome data from the pre-PSA era, and
the effects of screening, generational mortality improvements and radical treatment were incorporated. Sensitivities to the choice of
baseline data and values of key parameters were assessed. Lead-time estimates in men diagnosed aged 55–59 years were 14.1, 9.3
and 5.0 years for men with Gleason scores o7, 7 and 47, respectively, assuming biennial screening with 100% attendance. Central
estimates of 15-year prostate cancer mortality for conservative management of screen-detected prostate cancer ranged from 0 to
2% for Gleason scores o7, 9 to 31% for Gleason score 7 and 28–72% for Gleason scores 47. For men aged 55–59 years at
diagnosis, the predicted absolute 15-year survival benefit from curative treatment was 0, 12 and 26% for men with Gleason scores
o7, 7 and 47, respectively. Estimates of the survival benefit of radical treatment were relatively insensitive to values of key
parameters. The case for curative treatment, rather than conservative management, of screen-detected localised prostate cancer is
strongest in men with high-grade disease. This conclusion contrasts with current patterns of care.
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For most invasive cancers, effective curative treatment makes all
the difference between life and death. While prostate cancer can
follow an aggressive and ultimately fatal course, similar to that of
other cancers, a significant proportion of cases will behave in an
indolent fashion, with no impact either on health or longevity,
even in the absence of treatment. This effect is compounded by
competing causes of mortality in the typical age distribution
affected by prostate cancer. Partly for these reasons, it has been
difficult to establish whether radical treatment of prostate cancer
improves overall survival, and, if so, by how much.
Retrospective comparisons of curative treatment vs conservative
management of prostate cancer are of limited value, given the
likelihood of significant confounding variables. There are only two
published randomised controlled trials comparing expectant
management and definitive treatment of prostate cancer. Of these,
one, which included just 142 patients, is too small for meaningful
analysis (Iversen et al, 1995). The other, the Scandinavian Prostatic
Cancer Group Study Number 4, which opened in 1989, randomised
695 men with localised disease between radical prostatectomy and
watchful waiting (Bill-Axelson et al, 2005). Patients were aged less
than 75 years, with well or moderately differentiated, clinically
localised prostate cancer, a prostate-specific antigen (PSA) of less
than 50ngml
 1 and a life expectancy of at least 10 years. At a
median follow-up of 8.2 years, randomisation to radical prosta-
tectomy was associated with improved disease-specific mortality,
with a hazard ratio of 0.56 (95% CI: 0.36–0.88; P¼0.01), which
translated into an absolute overall survival benefit of 5.3% (95%
CI:  0.3 to 11.0%) at 10 years. Although the Scandinavian trial
provides the best available data comparing conservative manage-
ment and curative treatment, there are very major differences
between Scandinavian practice during the early 1990s and
contemporary clinical practice. In particular, the case-mix in the
trial was typical of clinically detected prostate cancer from the pre-
PSA era, with only 12% of patients having stage T1c disease. It is
therefore unclear how the results should be applied to men with
screen-detected prostate cancer.
Prostate-specific antigen screening results in overdetection (of
cases that would not otherwise have been detected) and introduces
a lead time (the time difference between screen detection and
clinical detection in the absence of screening), which may be of the
order of 10 years or more (Draisma et al, 2003). It follows that, in
the absence of treatment, the natural history of screen-detected
prostate cancer will appear more favourable than that of clinically
detected prostate cancer from the pre-PSA era. This is an important
consideration for men faced with the choice between conservative
management and curative treatment. In comparison with clinically
detected disease, men with screen-detected cancers will have longer
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sto endure any adverse effects of curative treatment, and longer to
wait for any beneficial effect on survival to emerge.
There are two ongoing randomised trials that aim to compare
curative treatment with conservative management in PSA screen-
detected disease. The Prostate Cancer Intervention versus Ob-
servation Trial (PIVOT) compares radical prostatectomy vs
watchful waiting, and is now closed to recruitment with 731
patients entered (Wilt and Brawer, 1995). The Prostate testing for
cancer and Treatment (ProtecT) study compares radical prosta-
tectomy, external beam radiotherapy and active monitoring, and
aims to recruit over 2000 patients (Donovan et al, 2003). The long-
term mortality outcomes from PIVOT and the ProtecT trial will
provide the best data concerning the effectiveness of curative
treatment of screen-detected disease, but will not be available for
some years. In the meantime, knowledge of the potential impact of
treatment on survival would be of great value to men found to have
screen-detected prostate cancer, and who are faced with the
decision whether or not to have curative treatment. We have
therefore undertaken a modelling exercise to estimate the natural
history of screen-detected prostate cancer, and the impact of
curative treatment on overall survival.
METHODS
We constructed a competing-risks model of hazard from mortality
to describe the natural history of prostate cancer from the pre-PSA
era, using terminology and results outlined in Anderson et al
(2002) (step one). We then adapted this model to incorporate the
lead time and the probability of overdetection associated with PSA
screening (step two), and generational improvements in all-cause
mortality (step three). We used this model, together with evidence
from the Scandinavian Prostatic Cancer Group Study (Bill-Axelson
et al, 2005), to make projections of the effect of curative treatment
on overall survival in contemporary patients with screen-detected
localised prostate cancer (step four). This approach is summarised
in Figure 1.
Step one: constructing the competing risks model
The hazard due to other-cause mortality under the given treatment
was allowed to vary with time by assuming a Weibull survival
distribution, with scale parameter lO and shape parameter g:
hO(t)¼lOg t
g 1. Disease-specific mortality was assumed, for
simplicity, to provide a constant hazard and therefore an
exponential survival distribution, with single parameter
lP:hP(t)¼lP, where t represents time since diagnosis. The total
hazard is the sum of the disease-specific and other-cause hazards:
h(t)¼hP(t)þhO(t). The model therefore requires estimates of
three model parameters.
Our model parameterisation does not directly account for age
and Gleason score, which are important covariates in modelling
survival from prostate cancer, so it was necessary to stratify the
model by these variables. To fit the model, we therefore required
long-term survival outcome data from conservative management
of prostate cancer, stratified by age group and Gleason score.
Average or smoothed proportions (so as to eliminate random
within-group variation) of the cohort alive, dead due to prostate
cancer and dead due to other causes at a given time point would be
sufficient to calculate two of the three parameters in the model,
conditional on a value for the other.
We reviewed the literature systematically for research that
would provide the necessary cohort survival data. Only one source
was found: Albertsen et al (1998, 2005) monitored the survival of
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Figure 1 Overview of methods.
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s767 men from the Connecticut Tumor Registry with localised
prostate cancer diagnosed between 1971 and 1984, treated
conservatively and followed up for a median of 24 years. Long-
term survival probabilities fitted by proportional hazards statis-
tical methods (Poisson regression over 15 years) were provided
(Table 3 of (Albertsen et al, 1998)), stratified by age at diagnosis
(within 5 years) and biopsy Gleason score (2–4, 5, 6, 7, 8–10).
Parameter g controls the rate of increase of other-cause hazard
over time rather than, directly, the level of a hazard, so is of less
interest than other parameters. We therefore decided to condition
our estimates for lO and lP on a value for g. The value for g was
estimated by fitting a single-risk Weibull model to 10000 survival
periods simulated from period analyses of three US life tables
(9–11), with initial ages sampled uniformly between 55 and 74
years inclusive. Model A assumed constant scale and shape
parameters across all age groups, model B additionally assumed
interaction between the scale parameter and age group and model
C additionally assumed interaction between the shape parameter
and age group. Fitted parameter values are shown in Table 1.
Being period life tables, it is uncertain how fitted parameter values
might relate to survival in a cohort. However, a single value of 1.8
was chosen for the shape parameter g as fitted values for the shape
parameter are close to this value in both 1979–1981 and 1989–1991
life tables, which cover periods close to those over which the
Albertsen study (Albertsen et al, 1998, 2005) was conducted.
We calculated lO and lP, conditional on g¼1.8, for each
stratum using an iterative numerical algorithm written specifically
for the task in Stata version 8.2 (Stata Corporation, College Station,
TX, USA), the software used throughout this paper. The model
relies in part on a reliable estimate of the shape parameter g. The
main end point, projected probability of survival at 15 years,
however, appears largely insensitive to small variations in this
parameter. Given a value for the parameter (g¼1.8), values of lO
and lP fitted to the data are detailed in Table 2.
Step two: adapting the model to allow for PSA screening
We adapted the model to allow for the lead time introduced by
PSA screening and the probability of overdetection. There are no
published data providing lead times and overdetection rates by
Gleason score and by age at diagnosis. The lead-time values and
overdetection proportions used for the model were taken as
average values simulated by a replica of the Markov lead-time
model fitted by Draisma et al (2003) for ‘relevant’ cases (detections
that were not overdetections), stratified by age (within 5 years) and
biopsy Gleason score (o7, 7, 47), assuming screening with 100%
attendance every 2 years. The replica model was tested to assess
how close its predictions of lead times and overdetection for
various screening programmes were to those quoted from the
original model (Draisma et al, 2003).
We averaged the fitted 15-year survival results from Albertsen
et al (1998) in the Gleason score 2–4, 5 and 6 groups, weighted
according to their sample size over those categories. By doing this,
Gleason score categories in our model corresponded with those in
Draisma et al (2003).
The survival outcomes for the overdetected proportion of cases
were calculated assuming hP(t) was equal to zero; for the ‘relevant’
cases, we calculated survival outcomes by setting hP(t) to be zero
for time t less than the lead time, and equal to lP otherwise. For
both groups, hO(t) was left unchanged in this step by using the
parameter values fitted in step one. Overall survival outcomes for
screen-detected cases were calculated as the average of the two sets
of survival outcomes figures, weighted according to the probability
of being in each group.
Step three: updating the model to a contemporary
population
Evidence of considerable reductions in mortality rates over the last
20 years can be found in US life tables (US Department of Health
National Center for Health Statistics and Human Services). In fact,
mortality at each age in every G7 country (Canada, France,
Germany, Italy, Japan, UK, US) has declined exponentially in the
last five decades at a roughly constant rate (Tuljapurkar et al,
2000). We accounted for mortality improvements in our modelling
by multiplying fitted values of lO and g, the two parameters in the
other-cause mortality function, by values informed through the
single-risk Weibull modelling of simulated life table survival data.
Table 1 Scale ( 100) and shape parameters fitted by the Weibull model of simulated survival from a period analysis of US life tables
Starting age group (years) Parameter 1979–1981 1989–1991 2002 Ratio 1989–1991:1979–1981 Ratio 2002:1979–1981
55–59 Scale 100 0.25 0.17 0.07 0.66 0.28
60–64 Scale 100 0.79 0.47 0.20 0.59 0.26
65–69 Scale 100 2.84 1.54 0.70 0.54 0.25
70–74 Scale 100 11.02 4.47 2.17 0.41 0.20
55–59 Shape 2.01 2.09 2.30 1.04 1.14
60–64 Shape 1.81 1.93 2.12 1.06 1.17
65–69 Shape 1.63 1.76 1.93 1.08 1.18
70–74 Shape 1.50 1.70 1.79 1.14 1.19
Table 2 Fitted values to the basic model from Albertsen’s data of parameters 100 lO (‘other’) and 100 lP (‘prostate’) given g¼1.8
Age at diagnosis (years)
55–59 60–64 65–69 70–74
Gleason score Other Prostate Other Prostate Other Prostate Other Prostate
o7 0.25 0.99 0.42 1.17 0.70 1.74 1.19 2.63
7 0.32 9.84 0.52 8.62 0.82 7.58 1.31 6.37
47 0.45 19.53 0.68 17.50 0.99 14.75 1.58 12.39
lO¼scale parameter; g¼shape parameter.
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sIn the central projections, the multipliers used were 0.25 and 1.15,
respectively, chosen through consideration of the ratios shown in
the final two columns of Table 1.
Step four: using the model to assess treatment benefit
In order to assess the benefit of curative as opposed to
conservative treatment, we required a model for mortality
following curative treatment. The Scandinavian Prostatic Cancer
Group Study assume in their analysis disease-specific hazards are
proportional in relation to treatment (Bill-Axelson et al, 2005), an
assumption we continued to adopt. We used their central estimate
of the hazard ratio, 0.56, as the value for our parameter HR.W e
assumed a hazard function due to disease-specific mortality such
that the disease-specific hazard ratio was equal to the parameter
HR for all age group and Gleason score strata at all times. The form
of the hazard function hQ(t) and its derivation are described in the
Appendix A.
Sensitivity analysis
To estimate the sensitivity of our results to the choice of baseline
treatment/data set, the procedure described above was repeated for
summary data from a Mayo Clinic study by Sweat et al (2002) of
the long-term survival with prostate cancer of 751 men after
radical prostatectomy, the only research found in the literature
providing the necessary cohort survival data in curatively treated
men. The same value of g was used as before. New values of lO and
lP were calculated based on reported fitted survival probabilities
by age group and Gleason score strata at 20 years using Cox
proportional hazards regression. As the base data relates to a
cohort given curative rather than conservative treatment, hP(t) was
the disease-specific hazard function under curative treatment and
hQ(t) the disease-specific hazard function under conservative
treatment with HR now equal to 1.79 (¼1/0.56).
To assess the sensitivity of results to key parameters, we have
also projected survival under ‘low’ and ‘high’ treatment benefit
scenarios. Relative to the central scenario, the ‘low treatment
benefit’ scenario assumes a higher overall survival hazard ratio for
curative treatment (0.7), a lower improvement over time in other
cause mortality (lo multiplier of 0.7 and g multiplier of 1.3), longer
lead times and greater overdetection rates; the ‘high treatment
benefit’ scenario assumes a lower hazard ratio (0.45), higher other-
cause mortality improvement (lo multiplier of 0.1 and g multiplier
of 1.0), shorter lead times and lower overdetection rates. The
sensitivity ranges for the hazard ratio, lead time and overdetection
rate were set as one standard deviation either side of the central
estimate. In doing this, we assumed lead times, the logarithm of the
hazard ratio and the logit of the overdetection rates were
distributed normally.
RESULTS
Constructing the model
Average lead times and overdetection rates by age at diagnosis and
by Gleason score from simulations of 1 million men with prostate
cancer by the replica of Draisma’s model (Draisma et al, 2003) for
biennial screening are shown in Table 4.
The discrepancies between average lead times presented from
Draisma’s original model (Draisma et al, 2003) and our replica
were found to be small: in the simulations, there was no more
difference in the projected mean lead times for all cases and
relevant cases only (cases of prostate cancer that would have been
clinically detected) than 0.3 years for single screens, 0.2 years for
schedules of annual screening and 0.3 years for schedules of
quadrennial screening. The proportions of detections that were not
‘relevant’ agreed within 4% for all screening programmes.
For biennial PSA screening, the predicted average lead times for
relevant cases were 9.9–14.1 years for cases with Gleason scores
o7, 8.0–9.3 years for those with Gleason score 7 and 5.0–6.0 years
for Gleason scores 47.
Projection results
Figure 2 shows projected survival over 15 years for contemporary
patients with PSA screen-diagnosed prostate cancer managed
conservatively, using the central model assumptions (based on
data from Albertsen et al (1998), with 100% attendance at biennial
screening and multipliers for lO and g of 0.25 and 1.15,
respectively). Mortality is divided by projected cause (prostate
cancer vs other). Table 3 provides survival projections at 15 years –
sections (i)–(iii) of the table relate to the natural history of
prostate cancer in conservatively treated men and section (iv)
relates to survival in curatively treated men. The projected
treatment effect, in terms of the absolute difference in 15-year
survival, is shown in section (v).
Under the central assumptions based on conservative manage-
ment, the probability of 15-year mortality from prostate cancer
appears strongly dependent on grade, particularly so for men who
are younger at diagnosis. For example, for men aged 55–59 years
at diagnosis, the projected 15-year prostate cancer mortality is 0%,
31% and 72% for men with Gleason scores o7, 7 and 47,
respectively. For men aged 70–74 years at diagnosis, the 15-year
prostate cancer mortality is projected to be 2%, 9% and 28% for
men with Gleason scores o7, 7 and 47, respectively.
The projected overall survival benefit from curative treatment
appears similarly dependent on Gleason score and age at
diagnosis. For example, for men aged 55–59 years at diagnosis,
the absolute 15-year survival benefit from curative treatment is
0%, 12% and 26% for men with Gleason scores o7, 7 and 47,
respectively. For men aged 70–74 years at diagnosis, the 15-year
overall survival benefit is projected to be 1%, 3% and 6% for men
with Gleason scores o7, 7 and 47, respectively.
Sensitivity analyses
Central projections of long-term survival probabilities together
with the range of outcomes projected from the high and low
scenarios using baseline data from either Albertsen et al (1998) or
Sweat et al (2002) are shown in Table 4 with the ranges of lead
times and overdetection rates assumed. While survival probabil-
ities based on data from Sweat are generally higher than those
based on data from Albertsen, likely due to differences in the case-
mix of the two studies, the point estimates are reasonably close and
there is considerable overlap in the range of projected survival
probabilities and absolute benefits, suggesting little sensitivity to
baseline data set. Ranges of survival projections across scenarios
are wide, but ranges of estimates of the absolute benefit due to
treatment are small, suggesting little sensitivity of absolute benefit
estimates to key parameter values. For example, the 15-year
absolute benefit of curative treatment to a man diagnosed at age
60–64 years with a Gleason 7 cancer is 9% (range across three
scenarios: 0–32%) based on Albertsen’s data (Albertsen et al,
1998) and 4% (range: 0–18%) based on Sweat’s data (Sweat et al,
2002).
DISCUSSION
This is the first study, to our knowledge, to model both the natural
history of screen-detected prostate cancer and the impact of
radical treatment on overall survival. While the outputs of the
model must be interpreted with caution, they may have important
implications for targeting treatment to those patients who stand to
benefit most. Specifically, the absolute survival benefit of radical
Impact of radical treatment on overall survival
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Figure 2 Projections of survival over 15 years under conservative treatment, using the central model assumptions. Black areas represent deaths due to
prostate cancer, grey areas represent deaths due to other causes.
Table 3 Central projections of 15-year outcome probabilities and absolute benefit of treatment (to nearest whole percentage point). (‘PC death’: death
attributed to prostate cancer)
Age at diagnosis (years)
55–59 60–64 65–69 70–74
Gleason score Alive Other death PC death Alive Other death PC death Alive Other death PC death Alive Other death PC death
(i) Original data – conservative treatment
o7 6 2 2 61 2 4 8 3 81 3 3 1 5 21 7 1 4 6 42 2
¼7 1 5 1 57 0 1 4 2 46 2 1 1 3 65 3 7 5 14 2
47 3 10 87 3 16 81 3 25 72 2 38 60
(ii) Conservative treatment, adjusting for screening (step two)
o7 71 28 1 57 42 1 39 60 1 20 79 1
¼7 4 2 3 12 7 3 7 4 51 8 2 7 6 31 0 1 5 7 9 6
47 1 1 2 56 4 1 1 3 85 1 1 2 5 73 1 7 7 51 8
(iii) Conservative treatment, allowing for screening and contemporary population (step three)
o7 84 16 0 74 25 1 61 38 1 43 55 2
¼7 5 2 1 73 1 5 0 2 72 3 4 5 4 01 5 3 5 5 6 9
47 1 5 1 37 2 1 8 2 16 1 2 3 3 54 2 2 0 5 22 8
(iv) Curative treatment, allowing for screening and contemporary population (step four)
o7 84 16 0 75 25 0 61 38 1 44 55 1
¼7 64 18 18 59 28 13 51 41 8 38 57 5
47 4 1 1 94 0 3 8 2 83 4 3 5 4 22 3 2 6 5 81 6
(v) Absolute differences: (iv) minus (iii)
o70 0 0 1 0  10 0 01 0  1
¼71 2 1  13 9 1  10 6 1  73 1  4
472 6 6  32 20 7  27 12 7  19 6 6  12
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streatment is predicted to be greater in men with high-grade
disease, whereas current clinical practice preferentially targets
radical treatment to patients with low-grade prostate cancer.
The central projections of the model based on Albertsen’s data
(Albertsen et al, 1998) are that the 15-year prostate-cancer-specific
mortality for men aged 55–74 years diagnosed with screen-
detected prostate cancer with a Gleason score of o7, and managed
conservatively, will be 1%, and the absolute benefit in 15-year
overall survival from curative treatment of such cases is predicted
to be less than 1%. The decision whether or not to have radical
treatment is a value judgement, comparing the known morbidity of
treatment with the potential survival benefit. Faced with a 30–60%
risk of treatment-related impotence, and a 0–1% 15-year
survival benefit, the majority of patients would decline radical
treatment (Singer et al, 1991). In fact, data from the Cancer of the
Prostate Strategic Urologic Research Endeavor (CaPSURE), an
observational database of prostate cancer patients from 35 US
centres, on 2078 cases diagnosed between 1989 and 2001 with
low-risk prostate cancer (serum PSA o/¼10ngml
 1, Gleason
sum o/¼6 and clinical T stage o/¼T2a), show that just 7.9% of
such men chose an observation policy, rather than treatment
(Cooperberg et al, 2004). One explanation for this pattern of care is
that patients and their clinicians have unrealistically high
expectations of the survival benefit from treatment of low-risk
disease, and this possibility deserves further study.
The model predicts that the absolute survival benefit of radical
treatment for screen-detected prostate cancer is greater in higher-
grade disease. This finding is consistent with observations from
retrospective studies. A population-based study from the SEER
database, based on data for 59876 cancer-registry patients aged
50–79 years who had clinically localised prostate cancer diagnosed
between 1982 and 1992, analysed disease-specific survival by grade
and by type of treatment (Lu-Yao and Yao, 1997) and found the
absolute difference in 10-year disease-specific survival between
radical prostatectomy and watchful waiting was 1, 10 and 22% for
grade 1, 2 and 3 disease, respectively. Similarly, a multicentre
comparison based on over 2000 patients, diagnosed between 1971
and 1984, observed a 10-year disease-specific survival difference
between radical prostatectomy and expectant management of 4%
for cases with Gleason score 2–4, 8% for scores 5–6, 17% for
scores of 7 and 19% for scores 8–10 (Barry et al, 2001). Patients
who select watchful waiting are very different from those who
select radical prostatectomy, and so retrospective comparisons
between them should be interpreted with great caution. However,
it is plausible that the differences between these two groups of
patients are independent of tumour grade. So, taken together with
the results of these retrospective studies, our model supports the
hypothesis that the absolute survival benefit of radical treatment is
greater for high-grade disease. These observations contrast with
current patterns of care for men with localised prostate cancer. Of
patients on the CaPSURE database with localised disease
diagnosed from 1999 to 2001, primary treatment was with radical
intent in 77.5, 75.8 and 47% of low-, intermediate- and high-risk
cases, respectively (Cooperberg et al, 2003).
The majority of prostate cancers detected by PSA screening are
low grade. Data on the grade-mix of screen-detected cancers from
second round and subsequent screens shows 76–85% of cases with
Gleason scores o7, 13–20% with a Gleason score of 7 and 1–4%
with Gleason scores 47 (Hoedemaeker et al, 2001; Hugosson et al,
2004; Makinen et al, 2004). Based on these figures, and given the
median age of detection of 67 years, our model predicts that the
absolute 15-year overall survival benefit for radical treatment,
compared with conservative management, of all screen-detected
localised prostate cancers will be approximately 1–2%. It is
noteworthy that the ongoing clinical trials addressing this issue
(PIVOT and ProtecT) are not adequately powered to detect a
survival benefit of this magnitude.
Nicholson and Harland (2002) have previously modelled the
natural history of screen-detected prostate cancer, based on
temporal trends in prostate cancer incidence and mortality at a
population level. They did not include consideration of the effect
of age and grade on lead times, generational improvements in all-
cause mortality or the impact of treatment on prostate cancer
outcomes. Notwithstanding these methodological differences, their
projections of 15-year disease-specific mortality for screen-
detected cancers diagnosed between ages 55 and 74 years, and
managed conservatively, ranged from 7.4 to 11.6%, which are
comparable to the current study.
The accuracy of our model is dependent on the validity of the
underlying assumptions. To model the natural history of PSA
screen-detected cancers, we have used published data to derive
estimates, by patient age and Gleason score, for survival outcomes
from expectant management in the pre-PSA era, and for lead times
and overdetection rates associated with PSA screening. The
Table 4 Projections of 15-year survival probabilities based on data from Albertsen et al (1998) and Sweat et al (2002): central estimates and ranges of
values obtained from low and high projections of life expectancy
Lead time
(years)
Overdetection
rate (%)
Albertsen data: survival
benefit (%)
Sweat data: survival
benefit (%)
Age group
(years)
Gleason
score Central
Sensitivity
range Central
Sensitivity
range Central
Sensitivity
range Central
Sensitivity
range
55–59 o7 14.1 5.2–22.1 37.1 6.9–82.4 0 0–5 0 0–6
¼7 9.3 2.8–15.1 16.1 1.2–74.5 12 0–36 5 0–17
47 5.0 1.1–9.6 7.3 0.2–78.6 26 1–48 12 0–23
60–64 o7 13.4 5.1–21.7 54.1 13.7–89.8 1 0–5 0 0–6
¼7 9.2 2.7–15.3 27.8 4–78.2 9 0–32 4 0–18
47 5.3 1.2–9.7 12.1 0.6–74.7 20 0–46 11 0–24
65–69 o7 11.8 4.4–20.1 66.9 19.4–94.4 0 0–7 0 0–4
¼7 9.0 2.7–15.2 43.5 9.3–85.3 6 0–27 3 0–15
47 6.0 1.4–10.1 25.8 3.4–77.4 12 0–40 6 0–22
70–74 o7 9.9 3.4–17.8 76.6 23.6–97.2 1 0–9 0 0–4
¼7 8.0 2.3–14.3 57.5 15.2–91.1 3 0–22 2 0–15
47 5.7 1.7–10.6 36.9 6.9–82.3 6 0–34 5 0–20
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management of localised disease from the pre-PSA era is highly
regarded on account of its size, the maturity of the outcome data
and the use of centralised pathology review with the Gleason
scoring system. However, 70% of patients in that series did not
have a staging bone scan, and there is evidence of systematic
upgrading in the interpretation of the Gleason grading system over
time (Smith et al, 2002; Kondylis et al, 2003). For both these
reasons, the data from Albertsen are likely an overestimate, rather
than an underestimate, of ‘true’ prostate cancer mortality from the
pre-PSA era. In any event, using the Mayo Clinic radical
prostatectomy data (Sweat et al, 2002), to describe the outcome
of prostate cancer from the pre-PSA era, does not materially affect
the outputs of the model. The model for estimating mean lead
times and overdetection rates was derived from MIcrosimulation
SCreening ANalysis (MISCAN) simulations of results validated
against data from the Rotterdam section of the European
Randomised Study of Screening for Prostate Cancer (ERSPC),
which enrolled 21166 men in the unscreened arm and 21210 men
in the screened arm and in which 1498 prostate cancers were
diagnosed. The Rotterdam screening policy evolved during the
study, but predominantly consisted of a sextant prostate biopsy for
men with a PSA 43ngml
 1. MISCAN models are based on
Markov processes of states and transitions and are designed to
evaluate cancer-screening programmes.
To model the absolute survival benefit of curative treatment in
the context of PSA screen detection, we used data from the only
randomised trial available, the Scandinavian Prostatic Cancer
Group Study. The hazard ratio for the effect of radical treatment on
prostate cancer mortality was taken to be 0.56 (95% CI: 0.36–0.88),
and this hazard ratio was assumed to be independent of tumour
grade and patient age. Subgroup analyses of the Scandinavian trial
are consistent with these assumptions (Bill-Axelson et al, 2005).
However, the trial consisted predominantly of patients with low-
grade disease, and included just 159 cases (23%) with Gleason
score 7, and 35 cases (5%) with Gleason score 47. A further
assumption is that the hazard ratio for the benefit of curative
treatment on prostate cancer mortality, derived from data on
patients with cancers typical of the pre-PSA era, is applicable to
patients with screen-detected cancers. In the absence of any data
on this issue, this is a significant limitation.
CONCLUSIONS
This modelling exercise, based on published data, describes the
natural history of screen-detected prostate cancer and the impact
of radical treatment on overall survival. The results of the model
should be interpreted with caution, since the original data upon
which it is based cannot necessarily be assumed to be generalisable
more widely. With that proviso, the 15-year mortality from low-
grade, screen-detected prostate cancer in men aged 55–74 years at
diagnosis, who elect conservative management, is projected in our
central model to be 1%, and the absolute 15-year survival benefit of
curative treatment, less than 1%. The absolute survival benefit for
radical treatment is predicted to be greater in men with high-grade
disease. When the results of PIVOT and the ProtecT trial are
mature, subgroup analysis by grade will be important. Until then,
the predictions of our model, together with the available
retrospective data, suggest that the case for radical treatment,
rather than conservative management, of localised prostate cancer
is strongest in men with high-grade disease.
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Appendix A
Marginal survival from death due to prostate cancer to time t since
diagnosis under conservative treatment is SP(t)¼exp( lPt).
Given a hazard ratio of HR, survival from death due to prostate
cancer to time t since diagnosis under curative treatment is
SQ(t)¼1 HR [1 exp( lPt)]. Noting that (Anderson et al,
2002) hQ(t)¼ d/dtlogSQ(t), we obtain hQ(t)¼{HRlPexp
( lPt)}/{1 HR [1 exp( lPt)]}.
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